Combination of anti-cancer drugs with molecular chaperone inhibitors

Maxim Shevtsov, Gabriele Multhoff, Elena Mikhaylova, Atsushi Shibata, Irina Guzhova, Boris Margulis

Research output: Contribution to journalReview articlepeer-review

45 Citations (Scopus)


Most molecular chaperones belonging to heat shock protein (HSP) families are known to protect cancer cells from pathologic, environmental and pharmacological stress factors and thereby can hamper anti-cancer therapies. In this review, we present data on inhibitors of the heat shock response (particularly mediated by the chaperones HSP90, HSP70, and HSP27) either as a single treatment or in combination with currently available anti-cancer therapeutic approaches. An overview of the current literature reveals that the co-administration of chaperone inhibitors and targeting drugs results in proteotoxic stress and violates the tumor cell physiology. An optimal drug combination should simultaneously target cytoprotective mechanisms and trigger the imbalance of the tumor cell physiology.

Original languageEnglish
Article number5284
JournalInternational journal of molecular sciences
Issue number21
Publication statusPublished - 2019 Nov 1
Externally publishedYes


  • Cancer therapy
  • Concurrent therapy
  • HSP27
  • HSP70
  • HSP90
  • Heat shock protein inhibitors
  • Molecular chaperones

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Combination of anti-cancer drugs with molecular chaperone inhibitors'. Together they form a unique fingerprint.

Cite this